Current Report Filing (8-k)
January 11 2022 - 8:27AM
Edgar (US Regulatory)
0001606498falseJanuary 11, 202200016064982022-01-112022-01-11
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report: January 11, 2022
(Date of earliest event reported)
AVANOS MEDICAL, INC.
(Exact name of registrant as specified in its charter)
Commission file number 001-36440
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Delaware
|
|
|
|
46-4987888
|
(State or other jurisdiction of incorporation)
|
|
|
|
(I.R.S. Employer Identification No.)
|
|
5405 Windward Parkway
|
|
|
Suite 100 South
|
|
|
Alpharetta,
|
Georgia
|
30004
|
|
|
(Address of principal executive offices)
|
(Zip code)
|
|
Registrant’s telephone number, including area code: (844) 428-2667
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
|
|
|
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
|
|
|
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock - $0.01 Par Value
|
AVNS
|
New York Stock Exchange
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure
On January 11, 2022, Avanos Medical, Inc. (the “Company”) posted an investor presentation to its website at https://avanos.investorroom.com/. A copy of the investor presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K. The presentation will be used by the Company in its prepared remarks at the J.P. Morgan Healthcare Conference. The presentation indicates that the Company’s 2021 adjusted earnings per share (“EPS”) will likely fall below the $1.10 to $1.20 per share guidance previously provided, as improved gross margins will finish short of expectations during the three months ended December 31, 2021. However, that statement does not take into account certain expected tax benefits. Inclusive of the additional expected tax benefits, the Company still anticipates EPS for the year ended December 31, 2021 to be in the guidance range of $1.10 to $1.20 per share.
The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed subject to the requirements of amended Item 10 of Regulation S-K, nor shall it be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing. The furnishing of this information hereby shall not be deemed an admission as to the materiality of any such information.
Item 9.01 Financial Statements and Exhibits
(d)Exhibits.
The following exhibits are filed with this Current Report on Form 8-K:
|
|
|
|
|
|
|
|
|
Exhibit No.
|
|
Description
|
|
|
|
104
|
|
Cover Page Interactive Data File (embedded within the inline XBRL document)
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
AVANOS MEDICAL, INC.
|
|
|
|
|
|
Date:
|
January 11, 2022
|
|
By:
|
/s/ S. Ross Mansbach
|
|
|
|
|
S. Ross Mansbach
Vice President, Deputy General Counsel and Corporate Secretary
|
Avanos Medical (NYSE:AVNS)
Historical Stock Chart
From Jul 2024 to Aug 2024
Avanos Medical (NYSE:AVNS)
Historical Stock Chart
From Aug 2023 to Aug 2024